BENZODIAZEPINES (BZO) QuickScreen™ One-Step Rapid Drug Screen Test (Cassette type) A Professional, Forensic Diagnostic Test for use in the Qualitative Detection of Benzodiazepines and their Metabolites in Human Urine at the Sensitivity Level of 200 ng/ml Established as Standard by the U.S. Department of Health and Human Services, DOT, World Health Organization and SAMHSA.

INTENDED USE

The QuickScreen™ One-Step Rapid Benzodiazepines Test is a rapid, visual, qualitative, competitive binding immunoassay for the detection of Benzodiazepines and Benzodiazepine metabolites in human urine. The test provides a fast confirmation of the presence of Benzodiazepines in the subject sample at a minimum cutoff sensitivity level of 200 ng/ml BZO, the sensitivity level set by the National Institute on Drug Abuse and Departments of Health and Human Services. Note: Where indicated, any positive test should be confirmed using quantitative methods by a qualified testing laboratory.
Note: This assay provides only a preliminary analytical test result. A more specific alternative chemical method such as high-pressure liquid chromatography (HPLC) or Gas chromatography/mass spectrometry (GC/MS) must be used in order to obtain a confirmed analytical result. For test situations requiring laboratory confirmation by such methods please refer to the QuickScreen Pro At Home Test Kit. Clinical consideration and professional judgment should be applied to all test results, particularly when preliminary positive results are indicated.

SUMMARY AND EXPLANATION OF THE TEST

Benzodiazepines can be insidious drugs of abuse because they are a frequently prescribed prescription drug. They represent a broad class of central nervous system depressants which have anxiolytic, hypnotic, anticonvulsant and muscle relaxant effects. Chronic abuse can result in addiction and retardive dyskinnesia. Benzodiazepines are used therapeutically to produce sedation, induce sleep, relieve anxiety and muscle spasms and to prevent seizures. In general, benzodiazepines act as hypnotics in high doses, as anxiolytics in moderate doses and as sedatives in low doses. Like the barbiturates, benzodiazepines differ from one another in how fast they take effect and how long the effects last. Shorter acting benzodiazepines, used to manage insomnia, include estazolam (ProSom), flurazepam (Dalmane), quazepam (Doral), temazepam (Restoril) and triazolam (Halcyon). Benzodiazepines with longer durations of action include alprazolam (Xanax), chlordiazepoxide (Librium), clorazepate (Tranxene), diazepam (Valium), halazepam (Paxipam), lorazepam (Ativan), oxazepam (Serax) and prazepam (Centrax). Abuse of Benzodiazepines occurs primarily because of the "high" which replicates alcohol intoxication. Approximately 50 percent of people entering treatment for narcotic or cocaine addiction also report abusing benzodiazepines. For comprehensive information on drug testing including typical half-life or drug detection periods see the Drug Testing FAQ.

The QuickScreen™ One-Step Rapid Benzodiazepines Test utilizes a unique combination of monoclonal antibodies to selectively identify Benzodiazepines and its major metabolites in urine with a high degree of sensitivity. The test kit is a rapid, visually read screening method that does not require special instrumentation or training.

PRINCIPLE

The QuickScreen™ One-Step Rapid Benzodiazepines Test technology incorporates a chromatographic absorbent device in which the drug or drug metabolites in the sample compete with a Benzodiazepines derivative immobilized on a porous membrane for limited antibody sites. This is the preferred scientific method for qualitative assay. In the assay procedure, urine mixes with labeled antibody-dye conjugate and migrates through test device. When Benzodiazepines levels are below 200 ng/ml (the detection cutoff sensitivity of the test) unbound antibody-dye conjugate binds to immobilized antigen conjugate in the Test Zone ("T"), producing a pink-rose colored band that indicates a negative result. Conversely, when Benzodiazepines levels are above the detection limit of 200 ng/ml, antibody-dye conjugate binds to the free drug, forming an antigen-antibody-dye complex. The complex competes with immobilized antigen conjugate in the Test Zone, preventing the development of a pink-rose colored band. Regardless of the test result, a color band is produced in the Control Zone ("C") by a non-specific sandwich dye conjugate reaction. This band serves as a built-in quality control by demonstrating antibody recognition, verifying that the reagents are chemically active, and confirming that the test was performed correctly.

MATERIALS PROVIDED:

Test Device and Dropper Pipette individually sealed in foil pouch with complete instructions.

ASSAY PROCEDURE

1. Collect a urine sample from test subject using a suitable clean container preferably glass.

2. Refrigerated specimens or other materials should be equilibrated to room temperature before testing.

3. Open the foil pouch at the notch, remove the test device, and label the device with specimen ID.

4. Holding the dropper vertically as shown, add 4 drops of urine into the sample well "S" waiting 5 seconds between drops.

5. Observe migration, or lateral flow of the sample across the entire test panel. Add additional sample drops if migration is not complete.

6. Positive results may be observed as soon as 5 minutes, depending on the concentration of Benzodiazepines in the tested specimen. To confirm negative results, a complete reaction time of 8-10 minutes is required. Do not interpret results after 15 minutes.

INTERPRETATION OF TEST RESULTS:

Positive. One (1) pink-rose band appears in the control zone and no band appears in the test zone. A positive result indicates the Benzodiazepines level is 200 ng/ml or higher in the test urine sample.
Negative. Two (2) pink-rose color bands appear, one in the control region and one in the test region. A negative result indicates that the Benzodiazepines level is below the detection sensitivity of 200 ng/ml. IMPORTANT: any line, no matter how faint, appearing in the test area confirms a negative test.
Invalid. If there are no distinct color bands visible in both the test zone and the control zone or if there is a visible band in the test zone but not in the control zone, then the test is invalid. In this instance, re-testing of the specimen is recommended.

TEST AVAILABILITY

The QuickScreen™ One-Step Rapid Benzodiazepines test is now available to professionals and individuals concerned with Benzodiazepines abuse. The test is one-step, fast, self-contained, individually packaged and can be performed any time the targeted drug use or abuse is suspected. The tests come in order units of five (5) individual tests at a cost per single diagnosis/screen of $4.00 for the minimum order unit. For testing situations where sample adulteration is suspect, a Rapid Urine Adulteration test is available.

Test Description/Type	Quantity	Cost
QuickScreen Benzodiazepines (BZO) Test	Five (5) Tests	$19.90
	Fifteen (15) Tests	$45.00
	Thirty (30) Tests	$75.00
	One Hundred (100) Tests	$190.00
	Two Hundred Fifty (250) Tests	$375.00
*If the order buttons are absent or inoperable, please use the pricing overview page to order.

Urine Sample Validity and Adulteration Test Strips are available: Adulteration Test

Professional specimen collection containers available separately: Specimen Containers